Warnings and Precautions Gallbladder abnormalities may occur. There have been postmarketing reports of cholelithiasis (gallstones) resulting in complications, including cholecystitis, cholangitis, ...
In this case-based conversation, Sandy Kotiah, MD, and Eric Liu, MD, FACS, discuss key symptoms of carcinoid syndrome, biomarker testing, differential diagnosis, and treatment with Sandostatin LAR Depot.
Oncology Nurse Elizabeth Cruz discusses treatment with Sandostatin® LAR Depot (octreotide acetate) for injectable suspension, including tips for mixing and administration, clinical data and safety information, and Novartis resources for patients.
Explore the history that led to the world’s first SSA* approved by the FDA for the severe diarrhea and flushing associated with metastatic carcinoid tumors. Take a look back at the years of research that led to the FDA approval of Sandostatin LAR Depot to reduce the severe diarrhea and flushing associated with metastatic carcinoid tumors.
FDA, US Food and Drug Administration; LAR, long-acting release; SSA, somatostatin analogue.
*Includes Sandostatin® (octreotide acetate) Immediate-Release Injection and Sandostatin LAR Depot for all approved indications.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Please see full Prescribing Information.
Indications and Usage
Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for
In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.